View Risk


Article data
Zhang (2020)
ACEI/ARB use and risk of infection or severity or mortality of COVID-19: A systematic review and meta-analysis
https://doi.org/10.1016/j.phrs.2020.104927
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227582/

Results
Treatment
Concomitant medication (Treated with ARBs vs. Not received)
COVID-19 (infection)
Odds ratio: 1.010 (0.950-1.070) Univariate analysis

Study characteristics

China, Italy, USA, Asia, Europe, and North America

A systematic review and meta-analysis

Review

19000

The twelve articles of seven cohort studies and five case-control studies. Together, the included articles evaluated more than 19,000 COVID-19 patients. The search strategy included clinical date published until May 9, 2020.

The overall average age of the subjects was greater than 60 years. Clinical outcomes were defined as COVID-19 infection in three studies, severity in severn studies, and mortality in eight studies. To provide a quantitative estimate of the association between ACEI/ARB use and severity or mortality risk in COVID-19 patients, the odds ratios (ORs) (most adjusted, if available) and the corresponding 95 % CIs were extracted from published articles. When the ORs were not given, tabular data were used to calculate the corresponding OR.

0


Results

COVID-19 (infection)

2048

COVID-19 infection

Treatment

Concomitant medication

When the studies were grouped by drug type, the risk of COVID-19 infection was not significantly increased among individuals exposed to ARB

Not received

Treated with ARBs

Odds ratio

1.010 (0.950-1.070)

No

No

No

Meta-analysis for ACEI/ARB use and risk of COVID-19 infection, COVID-19 Mortality, COVID-19 Severity. Pooled OR


Other information

To estimate overall risk, random-effects models were adopted. The results of the meta-analysis suggest that use of ACEI/ARB in patients with COVID-19 does not increase the risk of COVID-19 infection, severity, or mortality. However, a lower risk of mortality was observed among those patients who were taking ACEI/ARB for the treatment of hypertension. The findings suggest that ACEI/ARB treatment should be continued in COVID-19 patients who are taking these medications for antihypertensive treatment.

Average

Yes

Go Back